Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial

Background—In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, some patients with stable ischemic heart disease randomized to optimal medical therapy (OMT) crossed over to early revascularization. The predictors and outcomes of patients who crossed over from OMT to revascularization are unknown. Methods and Results—We compared characteristics of OMT patients who did and did not undergo revascularization within 12 months and created a Cox regression model to identify predictors of early revascularization. Patients’ health status was measured with the Seattle Angina Questionnaire. To quantify the potential consequences of initiating OMT without percutaneous coronary intervention, we compared the outcomes of crossover patients with a matched cohort randomized to immediate percutaneous coronary intervention. Among 1148 patients randomized to OMT, 185 (16.1%) underwent early revascularization. Patient characteristics independently associated with early revascularization were worse baseline Seattle Angina Questionnaire scores and healthcare system. Among 156 OMT patients undergoing early revascularization matched to 156 patients randomized to percutaneous coronary intervention, rates of mortality (hazard ratio=0.51 [0.13–2.1]) and nonfatal myocardial infarction (hazard ratio=1.9 [0.75–4.6]) were similar, as were 1-year Seattle Angina Questionnaire scores. OMT patients, however, experienced worse health status over the initial year of treatment and more unstable angina admissions (hazard ratio=2.8 [1.1–7.5]). Conclusion—Among COURAGE patients assigned to OMT alone, patients’ angina, dissatisfaction with their current treatment, and, to a lesser extent, their health system were associated with early revascularization. Because early crossover was not associated with an increase in irreversible ischemic events or impaired 12-month health status, these findings support an initial trial of OMT in stable ischemic heart disease with close follow-up of the most symptomatic patients. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00007657.

[1]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[2]  E. Braunwald,et al.  Economic Impact of Angina After an Acute Coronary Syndrome: Insights From the MERLIN-TIMI 36 Trial , 2009, Circulation. Cardiovascular quality and outcomes.

[3]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physi , 2012, Circulation.

[4]  K. Lee,et al.  Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. , 1994, The New England journal of medicine.

[5]  D. Berman,et al.  Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial , 2009, Circulation. Cardiovascular quality and outcomes.

[6]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[7]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[8]  Stanley E. Kaufman,et al.  Effect of PCI on quality of life in patients with stable coronary disease. , 2008, The New England journal of medicine.

[9]  S. Kaul,et al.  From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events. , 2007, The American journal of medicine.

[10]  R A Deyo,et al.  Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. , 1995, Journal of the American College of Cardiology.

[11]  G. Lamas,et al.  A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. , 1993, The New England journal of medicine.

[12]  J. Spertus,et al.  Monitoring the quality of life in patients with coronary artery disease. , 1994, The American journal of cardiology.

[13]  M. Hlatky,et al.  Differences in the treatment of myocardial infarction in the United States and Canada. A comparison of two university hospitals. , 1994, Archives of internal medicine.

[14]  Ron Goeree,et al.  Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients , 2008, Circulation. Cardiovascular quality and outcomes.

[15]  B. McNeil,et al.  Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. , 1997, The New England journal of medicine.

[16]  Benjamin S. Abella,et al.  Circ Cardiovasc Qual Outcomes , 2013 .

[17]  J. Spertus Selecting end points in clinical trials: What evidence do we really need to evaluate a new treatment? , 2001, American heart journal.

[18]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[19]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal odds ratios, Statistics in Medicine 2007; 26:3078–3094 , 2008 .

[20]  K A Eagle,et al.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.

[21]  D. Berman,et al.  Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. , 2006, American heart journal.

[22]  J. Spertus,et al.  ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Am , 2012, Journal of the American College of Cardiology.

[23]  P. O'Gara The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial: can we deliver on its promise? , 2010, Journal of the American College of Cardiology.

[24]  J. Spertus,et al.  ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Th , 2009, Journal of the American College of Cardiology.

[25]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[26]  Mario J. Garcia,et al.  ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[27]  R. Brook,et al.  Use of Coronary Artery Bypass Surgery in the United States and Canada , 1993 .

[28]  P. Austin The performance of different propensity score methods for estimating marginal odds ratios , 2007, Statistics in medicine.

[29]  Peter C Austin,et al.  A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.

[30]  D. Wennberg,et al.  Diagnostic-Therapeutic Cascade Revisited: Coronary Angiography, Coronary Artery Bypass Graft Surgery, and Percutaneous Coronary Intervention in the Modern Era , 2008, Circulation.

[31]  L. Leape,et al.  Regionalization and the underuse of angiography in the Veterans Affairs Health Care System as compared with a fee-for-service system. , 2003, The New England journal of medicine.

[32]  D. Berman,et al.  Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. , 2010, Journal of the American College of Cardiology.

[33]  J. Ornato,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Circulation.

[34]  R. A. Johnson,et al.  Prognostic value of a coronary artery jeopardy score. , 1985, Journal of the American College of Cardiology.

[35]  J. Spertus,et al.  Health Status Predicts Long-Term Outcome in Outpatients With Coronary Disease , 2002, Circulation.

[36]  D. Mozaffarian,et al.  Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. , 2003, American heart journal.